drugset / Trial / NCT02000609

A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of "Nexthaler" Dry Powder Inhaler in COPD Patients

NCT02000609

Phase 2 Completed 49 enrolled Chiesi Farmaceutici S.p.A.
RandomizedCrossoverDouble-blindTreatment

Summary

The study aim is to compare the pharmacodynamic effects (cardiovascular effects- primary variable: Heart rate over 4 hours post dosing- ) after administration of BDP and formoterol administered as CHF 1535 100/6 NEXThaler DPI or CHF1535 pMDI at two different dose levels.

Timeline

Start
2013-12
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Formoterol Other / unclassified 12 ug Inhaled
Comparator Formoterol Other / unclassified 48 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 200 ug Inhaled
Comparator beclomethasone dipropionate Other / unclassified 800 ug Inhaled